Actos MDL No. 2299 Convened for Status Conference in U.S. District Court in Louisiana

Actos MDL No. 2299 Convened for Status Conference in U.S. District Court in LouisianaParties involved in the Actos multi-district litigation (MDL) in the U.S. District Court for the Western District of Louisiana met for a Status Conference on January 24, 2013. The MDL is known as in re: Actos (Pioglitazone Products Liability Litigation) MDL No. 11-md-2299, and is being presided over by U.S. District Judge Rebecca F. Doherty.

During the most recent Actos MDL Status Conference, the court reviewed recent Actos filings in federal and state courts as well as any new developments since the Actos MDL’s last Status Conference in December 2012. According to an Actos MDL court document, the parties also discussed the progress of the discovery phase. The next Status Conference is scheduled for February 21, 2013.

Plaintiffs whose cases have been consolidated into the Actos MDL have filed their lawsuits against the manufacturer of Actos claiming that the drug caused serious health complications, including bladder cancer.

In a study conducted by Takeda Pharmaceuticals in collaboration with Kaiser Permanente, data shows an increased risk in the development of bladder cancer in patients who have been using Actos for more than 1 year. At this time, the FDA is reviewing information from the Takeda and Kaiser Permanente ten year study. In Europe, healthcare officials have banned sales of Actos following data released from a French epidemiological study that showed a strong link between the ingestion of Actos and the development of bladder cancer.

In other Actos related news, the manufacturer of Actos has received approval to sell a new diabetes drug in the U.S. According to a Bloomberg News report, the Japanese manufacturer of Actos, Takeda Pharmaceuticals, just received approval from the U.S. Food and Drug Administration (FDA) for a new diabetes medication known generically as alogliptin. Takeda Pharmaceuticals intends to market alogliptin in the U.S. by the brand name of Nesina.

Over a five year period, the FDA rejected the new diabetes medication twice before finally granting it approval this month. Whether this new diabetes drug comes with the risk of developing bladder cancer is still uncertain.

Lawyers at Carey Danis & Lowe are currently evaluating Actos claims. If you or someone you love has taken Actos and has subsequently developed bladder cancer, you may be eligible to receive recompense for your pain, suffering, medical expenses, and lost wages.

For a free legal evaluation about your Actos claim and to learn more about filing an Actos bladder cancer lawsuit, contact an experienced trial lawyer at Carey Danis & Lowe at 800.721.2519 today.

References: Actos, Pharmaceutical litigation
Tags: , , , , , , , , , , ,